Tag: FDA label update
-
FDA Requests Removal of Suicidal Behavior Warning from GLP‑1 Medications
Glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs) have become some of the most widely discussed medications in recent years – largely because of their role in weight loss and diabetes management. Drugs like Wegovy, Saxenda, and Zepbound have helped millions of people manage obesity and improve metabolic health. But until recently, these medications carried a warning